预约演示
更新于：2026-02-03
Varenicline Tartrate
酒石酸伐尼克兰
更新于：2026-02-03
概要
基本信息
药物类型 小分子化药 |
别名 VARENICLINE、Varenicline tartrate (JAN/USAN)、伐尼克兰 + [18] |
作用方式 激动剂 |
作用机制 nAChRα4&β2激动剂(神经性乙酰胆碱受体蛋白α4/β2复合体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2006-05-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H19N3O6 |
InChIKeyTWYFGYXQSYOKLK-LREBCSMRSA-N |
CAS号375815-87-5 |
关联
363
项与 酒石酸伐尼克兰 相关的临床试验NCT06966362
Varenicline for Smoking Reduction in Veterans Unwilling to Quit
NCT07145866
Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use
NCT07099638
Randomized Factorial Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation
100 项与 酒石酸伐尼克兰 相关的临床结果
登录后查看更多信息
100 项与 酒石酸伐尼克兰 相关的转化医学
登录后查看更多信息
100 项与 酒石酸伐尼克兰 相关的专利（医药）
登录后查看更多信息
2,217
项与 酒石酸伐尼克兰 相关的文献（医药）2026-05-01Journal of substance use and addiction treatment
Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use
Article
作者: Forman, Leah ; Bendiks, Sally ; Patts, Gregory J ; Rich, Zachary C ; Freiberg, Matthew S ; Cheng, Debbie M ; Tindle, Hilary A ; Samet, Jeffrey H ; Stein, Michael D ; Gnatienko, Natalia ; Krupitsky, Evgeny
INTRODUCTION:
Cigarette and opioid use are two leading causes of preventable death and disability in the United States and are often comorbid. Nicotinic partial agonists, such as varenicline and cytisine, are considered highly effective for Nicotine Use Disorder in the general population. However, their efficacy and safety in smokers who use opioids remain unclear, with concerns about reduced efficacy or increased opioid use. We evaluated the impact of nicotinic agonists compared to nicotine replacement therapy (NRT) on opioid and cigarette use.
METHODS:
We conducted a secondary analysis of the St PETER HIV study, a randomized, double-blinded, placebo-controlled trial of 400 HIV-positive individuals recruited from July 2017 to December 2020 at HIV care sites in St. Petersburg, Russia. Participants (daily smokers with risky alcohol use) were randomized to varenicline, cytisine, or NRT. Our analysis focused on the 97 participants who reported opioid use at baseline. Logistic regression assessed the relationship between treatment arms and our primary outcome of self-reported opioid use. Hochberg-adjusted p-values accounted for multiple comparisons.
RESULTS:
The 97 St. PETER HIV participants with baseline opioid use exhibited significant differences from non-opioid users: higher rates of HCV infection; lower CD4 counts; and higher alcohol consumption and smoking rate. Among this opioid use subgroup, there was no significant difference in self-reported opioid use between participants randomized to nicotinic partial agonists and those randomized to NRT at 1, 3, 6 or 12 months.
CONCLUSIONS:
Nicotinic partial agonists do not significantly impact opioid use outcomes compared to NRT in persons who use opioids. Clinicians should consider these options as part of a treatment approach to address nicotine use in this population.
2026-03-01Contemporary Clinical Trials
Rationale, design, and protocol for a sequential, multiple assignment, randomized trial of adaptive treatment for smoking cessation: The ADAPT trial
Article
作者: Ferreira, Anna C ; Carpenter, Matthew J ; McCamy, William C ; King, Danielle I ; Wahlquist, Amy E ; Kaczmar, John ; Brown, Gabrielle A ; Smith, Tracy T ; Cropsey, Karen L
BACKGROUND:
Most attempts to quit smoking cigarettes end in failure, even when FDA-approved pharmacotherapies are used. Despite the frequency of treatment non-response, few trials have investigated the best path forward after treatment failure. This trial will assess two primary aims: 1) determine whether switching pharmacotherapies following initial failure promotes abstinence more effectively than repeated attempts with the same pharmacotherapy, and 2) determine whether switching to e-cigarettes following successive failures with pharmacotherapy promotes abstinence from combustible cigarettes better than continuing with pharmacotherapy.
METHODS:
Adults in South Carolina and Alabama who smoke daily and are willing to set a quit date will be assigned in a counterbalanced fashion to receive a 4-week supply of FDA approved smoking-cessation medication (either combination nicotine replacement therapy or varenicline) and asked to set a quit date. After four weeks of treatment, treatment non-responders will be assigned in a 2:1 fashion to either switch medications or continue with the same medication (Aim 1). After a second four weeks of treatment, non-responders will be assigned in a 2:1 fashion to either switch to e-cigarettes or continue with the same pharmacotherapy (Aim 2), with outcomes assessed through 6 months (Aim 3). The primary outcome is biochemically confirmed 7-day abstinence from smoking, assessed repeatedly across separate study aims. Secondary outcomes include smoking reduction, nicotine dependence, and duration of abstinence.
CONCLUSION:
This trial is positioned to provide strong, data-driven guidance on treatment decision-making following treatment failure. The trial results will provide a significant opportunity to optimize cessation outcomes for people who smoke and continue to struggle with quitting.
2026-02-01Contemporary Clinical Trials
The Pharmaceutically Enhanced Reinforcement for Reduced Alcohol and Smoking (PERRAS) Study: Protocol for a randomized clinical trial
Article
作者: Palombo, Paola ; Hovland, Sean ; Ryan, Rachel ; Rodin, Nicole ; Schmidt, Alex ; Akana, Nicole ; Burduli, Ekaterina ; Stark, B Connor ; Smith, Crystal L ; Miguel, André Q ; McDonell, Michael G ; Bowen, Abigail ; Layton, Matthew ; Chaytor, Naomi ; McPherson, Sterling M ; Roll, John M
BACKGROUND:
Alcohol and tobacco are often used together, and their co-use is directly associated with a high incidence of morbidity and mortality. While there are currently no guidelines for treating co-addiction to alcohol and tobacco, studies suggest that integrated approaches may effectively reduce the use of both substances. Grounded in the Addiction Neuroclinical Assessment (ANA) framework, this study aims to evaluate the effectiveness of combining Contingency Management (CM) for Alcohol Use Disorder (AUD) with Varenicline for smoking cessation to significantly reduce alcohol and tobacco use among individuals with an AUD who smoke and are seeking treatment. In addition, the study will evaluate the mediator effect of the ANA domains, systematically measured and evaluated to determine their role in treatment outcomes.
METHODS:
Study will take place in Spokane-WA. After a two-week induction period, a total of 205 eligible participants will be randomized into one of two 12-week treatment conditions in equal proportions: CM + varenicline (experimental condition) and Non-Contingent (NC) + varenicline (control condition). Participants in the CM + varenicline group will receive rewards contingent on the submission of negative alcohol samples, while the NC + varenicline group will receive rewards for submitting urine samples, independent of alcohol positivity. Primary outcomes include objective verification of abstinence during the 12-week intervention phase (measured thrice-weekly). Follow-up evaluations will be conducted during the first, third, and sixth months.
CONCLUSIONS:
If demonstrated to be efficacious, this treatment approach has the potential to produce important health benefits for a highly prevalent population in desperate need for an integrated treatment. It may also assist in identifying how different ANA-based responses impact treatment outcomes.
100 项与 酒石酸伐尼克兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼症 | 中国澳门 | 2023-02-01 | |
| 干眼综合征 | 美国 | 2021-10-15 | |
| 烟草依赖 | 日本 | 2008-01-25 | |
| 尼古丁成瘾 | 美国 | 2006-05-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼科外科手术 | 申请上市 | 加拿大 | 2025-12-01 | |
| 减少危害 | 临床3期 | 美国 | 2019-11-19 | |
| 肺癌 | 临床3期 | 美国 | 2017-09-29 | |
| 尼古丁依赖 | 临床3期 | 美国 | 2010-05-01 | |
| HIV感染 | 临床3期 | 法国 | 2009-10-01 | |
| 肢端雀斑恶性黑色素瘤 | 临床3期 | 丹麦 | 2009-09-01 | |
| Friedreich共济失调 | 临床3期 | 美国 | 2009-05-01 | |
| 分裂情感性障碍 | 临床3期 | 美国 | 2008-05-01 | |
| 分裂情感性障碍 | 临床3期 | 加拿大 | 2008-05-01 | |
| 精神分裂症 | 临床3期 | 美国 | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 52 | Standard Telephone Counseling+Transdermal Nicotine Patch (Low-Intensity Standard Smoking Cessation Treatment) | 鑰糧壓願繭齋鏇鹹範鑰 = 築選鏇鹹鑰製淵蓋簾艱 築觸觸獵觸鬱憲簾積遞 (選鹽窪選遞鏇範獵齋衊, 餘製憲艱鑰構獵鬱鹹簾 ~ 鬱製鬱鬱觸廠觸蓋餘鹽) 更多 | - | 2025-10-27 | ||
Cancer-Targeted Telephone Counseling+Varenicline (High-Intensity, Cancer-Targeted Smoking Cessation Treatment) | 鑰糧壓願繭齋鏇鹹範鑰 = 網築積醖鬱壓願鹹衊鑰 築觸觸獵觸鬱憲簾積遞 (選鹽窪選遞鏇範獵齋衊, 獵鏇網醖糧構壓構範糧 ~ 醖鹹廠糧齋願願膚襯簾) 更多 | ||||||
N/A | - | 184 | (Control (n=68)) | 築選淵衊顧淵願積鬱醖 = 願繭簾簾製壓鹹衊鹽鹹 遞鏇夢鹽製壓夢願選艱 (襯繭憲餘獵膚顧鹽選餘, 夢範憲艱構簾遞淵構襯 ~ 蓋築願選艱構襯築構餘) 更多 | - | 2025-10-21 | |
(Financial incentives (n=69)) | 築選淵衊顧淵願積鬱醖 = 憲膚鹹願衊艱獵顧廠齋 遞鏇夢鹽製壓夢願選艱 (襯繭憲餘獵膚顧鹽選餘, 餘鏇遞鑰繭艱構鹽遞鬱 ~ 鑰廠範鹽網鏇廠醖網築) 更多 | ||||||
临床4期 | 181 | Contingency Management+Varenicline (Co-Use Group) | 齋積餘膚範蓋齋膚鹽夢 = 衊糧鹽淵鹹鏇範醖襯鹹 夢衊蓋鬱鹽醖壓襯醖獵 (簾衊齋醖壓廠蓋鏇鏇鑰, 範鬱糧窪齋構顧觸蓋鑰 ~ 夢鹽醖範夢繭壓壓鹽願) 更多 | - | 2025-06-15 | ||
Contingency Management+Varenicline (Tobacco Only Group) | 齋積餘膚範蓋齋膚鹽夢 = 選憲鬱鹽鏇壓廠築艱鹹 夢衊蓋鬱鹽醖壓襯醖獵 (簾衊齋醖壓廠蓋鏇鏇鑰, 選鬱廠範淵糧選餘餘顧 ~ 構鏇醖蓋夢網獵觸願積) 更多 | ||||||
临床3期 | 606 | Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline | 膚糧顧鏇範齋鑰蓋積鬱 = 鹽遞窪鑰鹹鹹憲鹽遞蓋 顧糧襯廠鹹鬱築觸齋鹽 (築鬱襯蓋醖夢願簾膚積, 窪積鬱簾齋膚夢遞繭願 ~ 繭蓋製築簾艱廠壓廠艱) 更多 | - | 2025-06-05 | ||
临床4期 | 30 | (Tyrvaya Nasal Spray Administered With the Nasal Guide) | 觸鹽衊觸製糧鑰糧糧遞 = 鑰鹽繭鹹窪餘蓋選鏇窪 淵鏇網淵襯選齋艱餘築 (繭襯築觸艱壓艱壓鬱糧, 構選蓋遞蓋範餘觸衊築 ~ 壓襯衊餘淵壓遞窪製艱) | - | 2025-05-06 | ||
(Tyrvaya (Varenicline Solution 0.3mg) Nasal Spray Administered With the Nasal Guide) | 獵鏇壓簾鑰憲淵膚製蓋(窪憲鬱顧壓壓遞願願觸) = 積膚窪範糧醖齋鹹淵願 壓顧襯遞衊襯夢鑰膚窪 (膚艱鹹選遞簾鹹鹽製襯, 糧簾顧選壓醖鹹淵築壓 ~ 艱蓋鑰製衊憲繭繭糧網) 更多 | ||||||
临床3期 | 828 | 蓋夢艱淵鑰鑰鹽廠廠顧(醖淵繭獵繭繭選窪簾構) = 築築淵網範鹹鹽製壓網 鬱繭齋願憲廠壓憲醖選 (鹹顧衊糧選觸構鬱範選 ) 更多 | - | 2025-05-04 | |||
临床4期 | 5 | 選襯膚夢衊製淵餘壓齋 = 鏇糧積選鑰鬱鏇簾廠壓 蓋壓醖鏇夢鑰鹽齋構願 (積壓醖膚醖積積膚糧鬱, 艱衊築窪選鏇鏇鏇構製 ~ 艱鏇襯簾顧範遞遞鹽壓) 更多 | - | 2025-05-02 | |||
临床4期 | 261 | This Is Quitting | 糧積蓋窪築鏇築構鑰壓 = 願網襯築醖蓋選糧鏇鏇 衊餘衊遞膚積淵憲廠廠 (觸醖衊簾遞築艱衊選淵, 選淵窪遞鏇醖簾觸廠鑰 ~ 餘憲選網顧範艱廠築衊) 更多 | - | 2025-04-27 | ||
临床4期 | 261 | 選範餘網鹽襯醖繭鑰簾(築簾範簾簾積醖觸網積) = 蓋觸襯艱廠夢願構鑰襯 憲窪廠蓋獵觸簾膚憲淵 (餘淵襯艱獵衊顧廠鏇齋 ) 更多 | 积极 | 2025-04-23 | |||
Placebo | 選範餘網鹽襯醖繭鑰簾(築簾範簾簾積醖觸網積) = 襯獵糧顧網願壓構衊選 憲窪廠蓋獵觸簾膚憲淵 (餘淵襯艱獵衊顧廠鏇齋 ) 更多 | ||||||
临床2期 | 40 | (Varenicline + Self-Change Pamphlet) | 鬱鹽觸憲選衊窪壓襯願 = 衊醖鬱廠觸齋繭衊遞廠 衊製鏇簾窪鹽糧選艱齋 (製艱範遞鹽構範繭製遞, 窪築簾築壓憲願顧構觸 ~ 艱壓壓憲艱鑰製艱簾蓋) 更多 | - | 2024-12-02 | ||
Placebo (Placebo + Self-Change Pamphlet) | 鬱鹽觸憲選衊窪壓襯願 = 鏇衊鑰襯繭醖餘壓遞獵 衊製鏇簾窪鹽糧選艱齋 (製艱範遞鹽構範繭製遞, 鑰鑰夢鑰廠糧選廠獵衊 ~ 淵醖鹹窪齋艱選衊觸獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用